Seattle Genetics Inc. CEO Clay Siegall envisions a broader collaboration with Bristol-Myers Squibb Co. on blood cancer combinations following the release of encouraging data for the anti-CD30 antibody-drug conjugate Adcetris and the PD-1 inhibitor Opdivo in relapsed Hodgkin lymphoma.
Adcetris (brentuximab vedotin), which is partnered with Takeda Pharmaceutical Co. Ltd., is approved for classical Hodgkin lymphoma after the failure of autologous hematopoietic stem cell transplantation (HSCT) and also...